IP Library › Granted Patent US 11,247,054
Granted Patent B2
US 11,247,054 · App. 16/472,215 · Granted Feb 15, 2022

Nanoparticles for use for enhancing brain performances or for treating stress

Inventors: Laurent Levy (Paris, FR); Marie-Edith Meyre (Saint Mande, FR); Agnès Pottier (Paris, FR)
Assignee: NANOBIOTIX S.A.
A61N1/36025A61K45/06A61N1/0456A61N2/006B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,247,054
App. No.
16/472,215
Granted
Feb 15, 2022
Kind
B2
Abstract

The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.

Claims (21)

1. A method for enhancing learning, memorizing, sense perception, attention and/or decision making or treating chronic stress in a subject, wherein the method comprises i) administering a nanoparticle or nanoparticle aggregate to the subject, the nanoparticle or nanoparticle aggregate material being selected from a metal having a standard reduction potential E° above 0.2 that is Ir, Pd, Pt, Au, or a mixture thereof, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or above 100, and wherein the nanoparticle and/or nanoparticle aggregate are coated with a biocompatible agent conferring a neutral surface charge, or with a biocompatible agent conferring a negative surface charge, and ii) exposing the nanoparticle or nanoparticle aggregate to an electric field applied through transcranial electric stimulation or transcranial magnetic stimulation.

2. The method according to claim 1 , wherein the material is an insulator material with a band gap Eg equal to or above 3.0 eV and the relative dielectric constant ε ijk , is measured between 20° C. and 30° C. and between 10 2 Hz up to the infrared frequency.

3. The method according to claim 2 , wherein the material is an insulator material with a band gap Eg equal to or above 3.0 eV and the relative dielectric constant ε ijk is equal to or above 200 and the material of the nanoparticle or nanoparticle aggregate is a dielectric material which is a mixed-metal oxide selected from BaTiO 3 , KTaNbO 3 , KTaO 3 , SrTiO 3 and BaSrTiO 3 .

4. The method according to claim 2 , wherein the material is an insulator material with a band gap Eg equal to or above 3.0 eV and the relative dielectric constant ε ijk is equal to or above 100 and the material of the nanoparticle or nanoparticle aggregate is a dielectric material which is selected from a metal oxide, a mixed metal oxide, the metallic element of which is from period 3, 5 or 6 of the Mendeleev periodic table or a lanthanide, and a carbon material.

5. The method according to claim 1 , wherein the nanoparticle or nanoparticle aggregate material is an insulator material with a dielectric constant ε ijk equal to or below 100 and is selected from Al 2 O 3 , LaAlO 3 , La 2 O 3 , CeO 2 , SiO 2 , SnO 2 , Ta 2 O 5 , ZrO 2 , HfO 2 and Y 2 O 3 .

6. The method according to claim 5 , wherein the nanoparticle or nanoparticle aggregate material is the insulator material with a dielectric constant ε ijk equal to or below 100 is selected from ZrO 2 and HfO 2 .

7. The method according to claim 1 , wherein the biocompatible agent conferring a neutral surface charge is a hydrophilic agent displaying a functional group selected from an alcohol (R—OH), an aldehyde (RCOH), a ketone (R—CO—R), an ester (R—COOR), an acid (R—COOH), a thiol (R—SH), a saccharide, glucose, fructose, ribose, an anhydride (RCOOOC—R), and a pyrrole.

8. The method according to claim 7 , wherein R is selected from a thiol, a silane, a carboxylic and a phosphate group.

9. The method according to claim 1 , wherein the biocompatible agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate is hydrophilic agent that is a monomer, a dimer, an oligomer, a polymer or a copolymer.

10. The method according to claim 9 , wherein the oligomer is an oligosaccharide.

11. The method according to claim 10 , wherein the oligosaccharide is cyclodextrin.

12. The method according to claim 9 , wherein the polymer is selected from a polyester, a polyether, a polyethylene oxide, a polyethylene glycol, a polyvinylalcohol, a polycaprolactone, a polyvinylpyrrolidone, a polysaccharide and a polypyrrole.

13. The method according to claim 12 , wherein the polyester is a poly(lactic acid) or a polyhydroxyalkanoic acid.

14. The method according to claim 12 , wherein the polysaccharide is cellulose.

15. The method according to claim 1 , wherein the biocompatible agent conferring a negative surface charge is a phosphate or a sulphate.

16. The method according to claim 15 , wherein the biocompatible agent conferring a negative surface charge is selected from a polyphosphate, a metaphosphate and a pyrophosphate.

17. A method for enhancing learning, memorizing, sense perception, attention and/or decision making or treating chronic stress in a subject, wherein the method comprises i) administering a composition to the subject, the composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support, and the nanoparticle or nanoparticle aggregate material being selected from a metal having a standard reduction potential E° above 0.2 that is Ir, Pd, Pt, Au, or a mixture thereof, an insulator material with a dielectric constant ε ijk equal to or above 200, and an insulator material with a dielectric constant ε ijk equal to or below 100, and wherein the nanoparticle and/or nanoparticle aggregate are coated with a biocompatible agent conferring a neutral surface charge, or with a biocompatible agent conferring a negative surface charge, and ii) exposing the subject to an electric field applied through transcranial electric stimulation or transcranial magnetic stimulation.

18. The method according to claim 17 , wherein the composition comprises at least two distinct nanoparticles and/or nanoparticle aggregates.

19. The method according to claim 17 , wherein the nanoparticle or nanoparticle aggregate material is an insulator material with a dielectric constant ε ijk equal to or below 100 and is selected from Al 2 O 3 , LaAlO 3 , La 2 O 3 , CeO 2 , SiO 2 , SnO 2 , Ta 2 O 5 , ZrO 2 , HfO 2 and Y 2 O 3 .

20. The method according to claim 19 , wherein the nanoparticle or nanoparticle aggregate material is the insulator material with a dielectric constant ε ijk equal to or below 100 is ZrO 2 or HfO 2 .

21. A kit comprising at least two distinct nanoparticles and/or nanoparticle aggregates, each nanoparticle or nanoparticle aggregate comprising a distinct material selected from a metal having a standard reduction potential E° above 0.2 that is Ir, Pd, Pt, Au, or a mixture thereof, an insulator material with a dielectric constant ε ijk equal to or above 200 and an insulator material with a dielectric constant ε ijk equal to or below 100, and wherein the nanoparticle and/or nanoparticle aggregate are coated with a biocompatible agent conferring a neutral surface charge, or with a biocompatible agent conferring a negative surface charge.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 049728 FRAME 0663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ENTIRE INTEREST. Recorded Dec 19, 2021
From: LEVY, LAURENT; MEYRE, MARIE-EDITH; POTTIER, AGNES
To: NANOBIOTIX S.A.
Reel/Frame 058548/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: LEVY, LAURENT; MEYRE, MARIE-EDITH; POTTIER, AGNES
To: NANOBIOTIX
Reel/Frame 049728/0663 →
Priority Claims (1)
EP 16306752 · Dec 21, 2016 · regional
Continuity (1)
Related Publication 20200086120A1 · Mar 19, 2020
Cited By (1)
US 12,653,890